<DOC>
	<DOCNO>NCT01371383</DOCNO>
	<brief_summary>The first part double-blind placebo-controlled trial identify effect omega-3 polyunsaturated fatty acid ( PUFAs ) monotherapy depression . The second part double-blind trial identify effect eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) different symptom cluster patient depression .</brief_summary>
	<brief_title>The Effect Fish Oil Major Depressive Disorder</brief_title>
	<detailed_description>With dissatisfaction monoamine-based pharmacotherapy high comorbidity physical illness depression , serotonin hypothesis seem fail approach etiology depression . Based upon evidence epidemiological data , case-control study PUFAs level human tissue , antidepressant effect clinical trial , phospholipid PUFAs enlighten promise path discover unsolved depression . The PUFAs classify n-3 ( omega-3 ) n-6 ( omega-6 ) group . Eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) , major bioactive component n-3 PUFAs , synthesize human obtain directly diet , particularly consume fish . The deficit n-3 PUFAs report associated neurological , cardiovascular , cerebrovascular , autoimmune , metabolic disease . Recent study reveal deficit n-3 PUFAs also associate depression . More specifically , society consume small amount omega-3 PUFAs appear high prevalence major depressive disorder . In addition , depressive patient show low level omega-3 PUFAs ; antidepressant effect PUFAs report number clinical trial . Theoretically , DHA deficit associate dysfunction neuronal membrane stability transmission serotonin , norepinephrine dopamine , might connect etiology depression . On hand , EPA important balancing immune function reduce membrane arachidonic acid ( AA , n-6 PUFA ) prostaglandin E2 ( PGE2 ) synthesis . Interestingly , animal feed high AA diet treat PGE2 present sickness behavior anorexia , low activity , change sleep pattern attention , similar somatic symptom depression human . There little data stage reveal whether oral administration omega-3 fatty acid monotherapy would lead effective mood stabilization major depressive disorder . In addition , active component antidepressant effect n-3 PUFAs still unknown . In project , first part double-blind placebo-controlled trial identify effect omega-3 PUFAs monotherapy depression . The second part double-blind trial identify effect EPA DHA different symptom cluster patient depression .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . DSMIV criterion major depressive disorder . 2 . Age age 1865 . 3 . Capacity willingness give write informed consent . 1 . Any major medical illness . 2 . A recent past history AxisI diagnose besides major depressive disorder , include psychotic disorder ; cognitively impair mental disorder ; impulse control disorder ; substance use disorder substance abuse ( last 6 month prior study ) ; primary anxiety disorder , include posttraumatic stress disorder panic disorder ; bipolar disorder ; AxisII diagnose , i.e . borderline antisocial personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>